Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2014147.pdf
Reference21 articles.
1. Brunello E, Bogina G, Bria E, Vergine M, Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi M, Manfrin E, Ibrahim M, Miller K, Tortora G, Molino A, Jasani B, Beccari S, Bonetti F, Chilosi M, Martignoni G, Brunelli M (2013) The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. J Cancer Res Clin Oncol 139 (9): 1563–1568.
2. Dendukuri N, Khetani K, McIsaac M, Brophy J (2007) Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176 (10): 1429–1434.
3. Dowsett M, Bartlett J, Ellis I, Salter J, Hills M, Mallon E, Watters A, Cooke T, Paish C, Wencyk PM, Pinder S (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridisation (FISH) for HER-2 in 426 carcinomas from 37 centres. J Pathol 199 (4): 418–423.
4. Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B (2009) Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 27 (18): 2962–2969.
5. Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, Tixier H, Guiu B, Penault-Llorca F, Ettore F, Fumoleau P, Arnould L (2010) Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer 103: 1335–1342.
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas;Human Pathology;2024-06
2. Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer;Diagnostic Pathology;2024-02-15
3. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer;Journal of Translational Medicine;2023-06-01
4. Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers;Frontiers in Oncology;2022-10-31
5. A Soft Label Deep Learning to Assist Breast Cancer Target Therapy and Thyroid Cancer Diagnosis;Cancers;2022-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3